home / stock / acet / acet message board
Subject | By | Source | When |
---|---|---|---|
AviseAnalytics: 7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST! $ACET Adicet Bio (NASDAQ: ACET) i | AviseAnalytics | investorshangout | 01/24/2022 12:25:33 PM |
No sell off...guess I bet wrong | masterofdisaster | investorshub | 12/08/2021 7:41:01 PM |
Phase 1's usually suck wind, I lost $80K | TheFinalCD | investorshub | 12/08/2021 2:58:31 PM |
It was weird....I think the MMs drop this | masterofdisaster | investorshub | 12/08/2021 12:07:16 PM |
whats weird is the rally after the offering | TheFinalCD | investorshub | 12/08/2021 4:10:48 AM |
Bought puts today anticipating an offering and there | masterofdisaster | investorshub | 12/07/2021 10:09:39 PM |
13.20 low start | TheFinalCD | investorshub | 12/07/2021 9:40:20 AM |
14.20 in AH. Nice day for the clinical | crudeoil24 | investorshub | 12/07/2021 1:04:22 AM |
thanks for creating the board | TheFinalCD | investorshub | 12/07/2021 12:12:11 AM |
Adicet Bio shares are trading higher after the | crudeoil24 | investorshub | 12/06/2021 11:04:36 PM |
Adicet Bio Inc. is a biotechnology company that | crudeoil24 | investorshub | 12/06/2021 11:03:47 PM |
znewcar1: ACET 38% v48,2M c13.57 f31,9M H15.67 S12.7 | znewcar1 | investorshangout | 12/06/2021 9:22:41 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 06:49:48 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Adicet Bio, Inc. (Nasdaq: ACET ) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell The...
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) applicatio...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuit...